ImmuneRegen BioSciences(R) Reports Additional Positive Results From Study of Homspera(R) in Treating Highly Pathogenic Influenza
January 05 2010 - 8:00AM
Marketwired
ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR
Biosciences Holdings Inc. (OTCBB: IRBS), today announced additional
positive results from a recent study that evaluated its lead
anti-influenza drug, Homspera®, in ferrets. Performed at a public
University under the guidance of a world-renowned influenza expert,
the study utilized a 'real-world' scenario of highly pathogenic
influenza infection by a clade 2.2 H5N1 virus
(A/Whooperswan/Mongolia/244/2005), and drug treatment beginning one
day following influenza infection, coinciding with emergence of the
first symptoms. These newly obtained data reveal Homspera treatment
resulted in a decrease in viral titers (concentration of virus
particles) at 5 days post-infection, indicative of an anti-viral
effect of Homspera. Previously reported findings from this study
revealed that Homspera treatment starting 1 day following influenza
infection dramatically reduced symptoms of influenza infection and
increased survival by 60% over infected controls.
"These new findings are exciting," stated ImmuneRegen Vice
President and Chief Scientific Officer Hal Siegel. "The reduction
in viral titers in the Homspera-treated animals complements the
reductions in symptom severity and increases in survival we
announced previously and provides credence to the anti-viral
mechanism of action of Homspera we've hypothesized. We previously
showed reductions in nasal virus titer in cotton rats infected with
seasonal influenza, and inhibition of the lung damage in mice and
rats as is typically seen in influenza infection. These data from
highly pathogenic influenza virus infection in ferrets provide
further support that Homspera treatment reduces viral titers and
improves recovery and survival in models of influenza infection. We
are focused on ways to aggressively advance this program toward the
clinic."
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera® and its derivatives. Homspera is an adult
stem cell active compound that in study results has been shown to
regenerate and strengthen the immune system and enhance wound
healing. Viprovex®, a derivative of Homspera, is being developed
for potential use against infectious diseases as a stand-alone or
combination therapy and as a vaccine adjuvant. To advance its
mission, the Scottsdale, Arizona based company has forged numerous
study partnerships with industry and academic leaders, including
Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory
Research Institute and Virion Systems. For more information, please
visit www.immuneregen.com.
Statements about the Company's future expectations, including
statements about the potential use and scientific results for the
Company's drug candidates, science and technology, and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby. These future events may not occur as and when expected, if
at all, and, together with the Company's business, are subject to
various risks and uncertainties. The Company's actual results could
differ materially from expected results as a result of a number of
factors, including the uncertainties inherent in research and
development collaborations, pre-clinical and clinical trials and
product development programs (including, but not limited to the
fact that future results or research and development efforts may
prove less encouraging than current results or cause side effects
not observed in current pre-clinical trials), the evaluation of
potential opportunities, the level of corporate expenditures and
monies available for further studies, capital market conditions,
and others set forth in the Company's periodic report on Form 10-Q
for the three months ended September 30, 2009 as filed with the
Securities and Exchange Commission and report on Form 10-K for the
year ended December 31, 2008 as filed with the Securities and
Exchange Commission. There are no guarantees that any of the
Company's proposed products will prove to be commercially
successful. The Company undertakes no duty to update
forward-looking statements.
Contact: Michael K. Wilhelm OR John Fermanis ImmuneRegen
BioSciences Inc. Phone: 480-922-3926 Email: Email Contact Email:
Email Contact
IR BioSciences (CE) (USOTC:IRBS)
Historical Stock Chart
From May 2024 to Jun 2024
IR BioSciences (CE) (USOTC:IRBS)
Historical Stock Chart
From Jun 2023 to Jun 2024